In the phase 2 trial, efficacy was also seen in patients with non-atopic chronic hand eczema treated with the oral JAK ...

And how many of them are needed to build a house of cards? Just one — if you're willing to decorate it with decimals and call it science. A global analysis claims plastics are responsible for 13.497% ...

(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months ...

Neoadjuvant Opdivo with chemotherapy significantly improves overall survival in resectable NSCLC compared to chemotherapy alone, as shown in the CheckMate-816 study. The study's primary endpoints, ...

Princess U. Ogbogu, Division Chief of Pediatric Allergy, Immunology, and Rheumatology at University Hospitals Rainbow Babies and Children’s Hospital and Case Western Reserve University, Cleveland, OH, ...

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Frontiers in ...

Artificial intelligence giant Anthropic has admitted the industry may be displacing young graduates from jobs, conceding ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat ...

ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078) ENLIGHTEN 2 ...

Treatment with QP-6211 achieved primary and all key secondary endpoints in both placebo- and active-controlled Phase 3 trials following hemorrhoidectomy or bunionectomy. QP-6211 demonstrated ...